How to Push Adenosine: Procedure, Dosing, and Safety

Adenosine must be pushed fast, as a rapid intravenous bolus followed immediately by a saline flush, because the drug is broken down by red blood cells within seconds of entering the bloodstream. The whole point of the technique is to deliver a concentrated slug of medication to the heart before the body destroys it. With a half-life measured in seconds, even a slight delay in administration can mean the drug never reaches therapeutic levels at the atrioventricular (AV) node, and the arrhythmia continues unchecked. Getting the push right is just as important as getting the dose right.

Why Speed Is Everything

Adenosine works by briefly blocking electrical conduction through the AV node, which interrupts the re-entrant circuit responsible for most episodes of supraventricular tachycardia (SVT). In pooled data from over 600 reported episodes, rapid bolus administration converted SVT to normal sinus rhythm about 93% of the time.¹ That success rate depends entirely on the drug arriving at the heart in a concentrated wave. Red blood cells are remarkably efficient at mopping up adenosine from the blood. In laboratory conditions, erythrocytes can strip adenosine from surrounding fluid in under a minute at low concentrations.² In a living person with full circulation, that breakdown is even faster, which is why the drug’s clinical half-life is only a few seconds.

This ultrashort duration is actually one of adenosine’s greatest strengths. Unlike other antiarrhythmic drugs that linger in the system and carry prolonged side-effect profiles, adenosine’s effects are essentially over within 10 to 20 seconds. If it works, the arrhythmia breaks almost immediately. If it does not work, the window has already closed, and you can try again at a higher dose without worrying about drug accumulation.

The Push Technique Step by Step

The standard method uses two syringes connected to an IV line as close to the patient’s vein as possible, ideally through a stopcock at the IV hub. One syringe holds the adenosine dose; the other holds a normal saline flush, usually 10 to 20 mL for adults. The adenosine is pushed hard and fast over one to two seconds, and the saline flush follows instantly, pushed just as aggressively, to chase the drug into the central circulation before the blood can metabolize it. Both pushes happen at the IV port nearest the patient, not further up the tubing, to minimize transit time.

There has been ongoing discussion about whether a single-syringe technique, where the adenosine and flush are pre-loaded into one large syringe, might be faster than the traditional two-syringe method. A simulation study in a pediatric model found that the single-syringe approach cut the total administration time roughly in half, with a median of about 13 seconds compared to about 26 seconds for two syringes.³ In practice, many emergency departments still use two syringes because clinicians are comfortable with the technique and it allows more precise dose measurement. The single-syringe method may have an edge in situations where speed is especially tight, such as when IV access is in the hand or foot rather than near the heart.

Regardless of technique, the IV site matters. An antecubital vein (inside the elbow) is preferred because it provides a shorter, more direct route to the heart than a hand or wrist IV. When using a peripheral line, elevating the arm immediately after the push can help speed delivery.

Adult Dosing

The standard adult protocol starts with 6 mg as a rapid IV push. If the arrhythmia does not convert within one to two minutes, a second dose of 12 mg is given. A third 12 mg dose can follow if needed. This escalating approach was established in early dose-ranging trials that tested sequential boluses of 3, 6, 9, and 12 mg against placebo and compared adenosine’s effectiveness with verapamil.⁴

Some protocols include a smaller initial dose of 3 mg, particularly when the clinician suspects the patient may be especially sensitive, for instance due to a central line or recent heart transplant. For most patients presenting in the emergency department with a peripheral IV, though, 6 mg is the standard starting point. The maximum single dose is 12 mg, and there is little evidence that going higher provides additional benefit.

Pediatric Dosing

Children receive weight-based doses rather than flat milligram amounts. The traditionally recommended starting dose is 0.1 mg/kg, with dose increases up to 0.2 or 0.3 mg/kg if the first attempt fails, capped at a maximum single dose of 12 mg. Early studies found that only about 16% of children converted at 0.05 mg/kg, while roughly 35% converted at 0.1 mg/kg, supporting 0.1 mg/kg as a more reasonable starting point.⁵

Even at the commonly used starting doses, however, conversion rates in children are far from perfect. A recent systematic review and meta-analysis across multiple pediatric cohorts found that conversion probability increased steadily with higher weight-based doses: roughly 25% at doses below 0.1 mg/kg, about 38% at 0.1 mg/kg, around 47% at 0.15 to 0.225 mg/kg, and approximately 59% at 0.25 to 0.4 mg/kg.⁶ The implication is that commonly used initial doses underperform in many children, and future protocols may shift toward higher starting doses, though prospective trials are still needed to confirm the right balance of effectiveness and safety.

Central Lines Change the Equation

When adenosine is given through a central venous catheter rather than a peripheral IV, it reaches the heart much faster and with far less degradation along the way. A study comparing the two routes in the same patients found that 77% of SVT episodes were terminated with just 3 mg centrally, compared to only 37% peripherally. Overall, about 63% of patients needed a lower dose when the drug was given centrally, and none required 12 mg through a central line.⁷

This has real clinical consequences. A case report described a patient with a port-a-cath who was given the standard 12 mg dose through the central line and experienced 13 seconds of severe bradycardia with significant side effects. When the same patient returned two weeks later with recurrent SVT, just 3 mg through the same central line terminated the arrhythmia cleanly.⁸ The practical rule: if your patient has a central line, start low, typically at 3 mg for adults, and titrate up cautiously.

What the Patient Feels

Patients who receive adenosine almost universally experience unpleasant sensations, though they pass quickly. The most commonly reported effects include chest tightness or pressure, a feeling of impending doom, flushing, shortness of breath, and palpitations. Some patients describe a brief sensation that their heart has stopped, which in a sense it has; the AV block creates a momentary pause in the heartbeat before sinus rhythm resumes. These symptoms resolve within seconds, but they can be alarming for someone who was not warned.

Premedication with a small dose of a benzodiazepine has been studied as a way to blunt these subjective effects. A randomized trial found that midazolam given before adenosine significantly reduced complaint scores for palpitations and chest pain, with trends toward improvement in other symptoms as well.⁹ In practice, premedication is not standard in emergency settings because speed often takes priority, but it is worth considering when the clinical situation allows a brief preparation period.

Telling the patient what to expect before the push is simple and effective: “You’re going to feel strange for a few seconds. You might feel pressure in your chest, warmth in your face, or a brief sensation that your heart stops. It will pass very quickly.” This kind of warning does not eliminate the discomfort, but it can prevent the panic that comes from an unexplained sensation of cardiac arrest.

The Post-Push Pause

After successful conversion, most patients have a brief sinus pause, that moment of electrical silence before the heart’s natural pacemaker kicks back in. One emergency department study measured these pauses and found a median duration of about 1,240 milliseconds, which is just over a second. Interestingly, obese patients tended to have shorter pauses than non-obese patients, possibly because a standard dose is diluted across a larger blood volume.¹⁰ A pause of one to two seconds is normal and expected. Prolonged pauses, beyond several seconds, are uncommon and more likely to occur when the dose is higher than needed, as in the central line scenario described earlier.

In pediatric safety data spanning ten years across multiple hospitals, some children had brief runs of ventricular beats after adenosine, but none required treatment, and no patient experienced syncope or sustained hemodynamic instability.¹¹ Still, adenosine should only be given in a monitored setting with resuscitation equipment at hand. The drug is safe, but the arrhythmias it treats are not trivial, and having defibrillation capability immediately available is non-negotiable.

Drug Interactions That Matter

Two categories of drug interactions are clinically significant: substances that block adenosine’s effect and substances that amplify it.

Caffeine and theophylline are competitive antagonists at adenosine receptors. A study measuring forearm blood-flow responses showed that caffeine significantly reduced adenosine-induced vasodilation in a dose-dependent manner, and theophylline did the same.¹² In clinical terms, a patient who drinks large amounts of coffee or is on theophylline for lung disease may not respond to the standard starting dose. Higher doses or alternative agents may be necessary. The textbook advice is to consider higher initial dosing in patients on methylxanthines, though there is no universally agreed-upon dose adjustment.

On the other side, dipyridamole (a medication sometimes given to prevent blood clots, especially in people with mechanical heart valves) blocks the cellular uptake and breakdown of adenosine, effectively multiplying its potency. Laboratory work has shown that dipyridamole shifts the adenosine concentration-response curve significantly to the left, meaning less adenosine is needed to produce the same effect.¹³ In patients on dipyridamole, starting with a lower dose, often halved, is the standard precaution. Carbamazepine, an anti-seizure medication, can have similar potentiating effects and warrants the same caution.

When Not to Give Adenosine

The most important absolute contraindications are second- or third-degree heart block (without a functioning pacemaker) and sick sinus syndrome, because the drug’s mechanism of action is to temporarily block AV conduction. In a patient whose conduction system is already compromised, that could result in a dangerously prolonged pause or asystole.

Asthma and severe reactive airway disease are relative contraindications. Adenosine stimulates receptors in bronchial smooth muscle that can trigger bronchoconstriction, and there are case reports of respiratory failure following administration in patients with pre-existing airway disease.¹⁴ The bronchospasm, like adenosine’s other effects, resolves quickly, but in a patient already struggling to breathe it can be enough to tip the balance. Alternative agents such as calcium channel blockers are usually preferred for these patients.

Heart Transplant Recipients

Patients who have had a heart transplant present a unique challenge. The surgical process severs the vagus nerve’s connection to the donor heart, leaving the transplanted organ’s sinus and AV nodes without their usual parasympathetic input. This denervation causes the adenosine receptors on those nodes to become supersensitive. Studies have shown that the transplanted sinus node responds three to six times more strongly to adenosine than a normal heart, and the effects last three to five times longer.¹⁵

Because of this supersensitivity, adenosine has traditionally been considered relatively contraindicated in transplant patients. More recent work has shown it can be used safely, but at dramatically reduced doses. A prospective study in pediatric and young adult transplant patients found that one-quarter of the standard starting dose, about 25 mcg/kg for children or 1.5 mg for young adults over 60 kg, was both safe and effective.¹⁶ If you are treating SVT in a transplant patient and adenosine is the best option, start at one-quarter of the usual dose and have transcutaneous pacing pads in place.

Adenosine as a Diagnostic Tool

Beyond converting SVT, adenosine has a role in diagnosing the cause of a rapid heart rate. When a patient presents with a wide-complex tachycardia and the underlying rhythm is unclear, a bolus of adenosine can help. If the tachycardia is actually SVT with aberrant conduction (the electrical signals taking an unusual path through the ventricles), adenosine will likely terminate it. If it is ventricular tachycardia, adenosine generally will not affect it, but the brief AV block can unmask the underlying atrial activity on the ECG strip, helping to clarify the diagnosis.¹⁷

Adenosine is also widely used outside the emergency department as a pharmacologic stress agent for cardiac imaging. In patients who cannot exercise on a treadmill, an adenosine infusion dilates the coronary arteries, allowing imaging techniques to detect areas of the heart muscle that are not getting adequate blood flow. This application uses a continuous infusion rather than a bolus, but the pharmacologic principle is the same: the drug’s short half-life makes it easy to control and quick to reverse if problems arise.¹⁸

When the First Dose Fails

A failed first dose does not mean adenosine is the wrong drug. The most common reason for failure is a technical problem with the push itself: too slow an injection, too much IV tubing between the port and the patient, or an IV site in the hand or foot that allows excessive drug degradation in transit. Before escalating the dose, it is worth confirming that the IV is running well, the push was truly rapid, and the flush followed immediately. Repeating the same dose with better technique sometimes works when escalating would not have been needed.

That said, some patients genuinely need higher doses. People with high caffeine intake, those on theophylline, and patients with higher body mass may all require the 12 mg ceiling. If two rounds of 12 mg fail with good technique through a well-positioned peripheral IV, the tachycardia may not be the type that responds to adenosine, and alternative agents or synchronized cardioversion should be considered. The beauty of adenosine is that its fleeting duration means you have lost very little time finding this out.